Brown A M, Tummolo D M, Spruyt M A, Jacobsen J S, Sonnenberg-Reines J
CNS Disorders, Wyeth-Ayerst Research, Princeton, New Jersey 08543, USA.
J Neurochem. 1996 Jun;66(6):2436-45. doi: 10.1046/j.1471-4159.1996.66062436.x.
No single protease has emerged that possesses all the expected properties for beta-secretase, including brain localization, appropriate peptide cleavage specificity, and the ability to cleave amyloid precursor protein exactly at the amino-terminus of beta-amyloid peptide. We have isolated and purified a brain-derived activity that cleaves the synthetic peptide substrate SEVKMDAEF between methionine and aspartate residues, as required to generate the amino-terminus of beta-amyloid peptide. Its molecular size of 55-60 kDa and inhibitory profile indicate that we have purified the metalloprotease EC 3.4.24.15. We have compared the sequence specificity of EC 3.4.24.15, cathepsin D, and cathepsin G for their ability to cleave the model peptide SEVKMDAEF or related peptides that contain substitutions reported to modulate beta-amyloid peptide production. We have also tested the ability of these enzymes to form carboxyl-terminal fragments from full-length, membrane-embedded amyloid precursor protein substrate or amyloid precursor protein that contains the Swedish KM --> NL mutation. The correct cleavage was tested with an antibody specific for the free amino-terminus of beta-amyloid peptide. Our results exclude EC 3.4.24.15 as a candidate beta-secretase. Although cathepsin G cleaves the model peptide correctly, it displays poor ability to cleave the Swedish KM --> NL peptide and does not generate carboxy-terminal fragments that are immunoreactive with amino-terminal-specific antiserum. Cathepsin D does not cleave the model peptide or show specificity for wild-type amyloid precursor protein; however, it cleaves the Swedish "NL peptide" and "NL precursor" substrates appropriately. Our results suggest that cathepsin D could act as beta-secretase in the Swedish type of familial Alzheimer's disease and demonstrate the importance of using full-length substrate to verify the sequence specificity of candidate proteases.
尚未出现一种具备β-分泌酶所有预期特性的单一蛋白酶,这些特性包括脑定位、合适的肽切割特异性以及在β-淀粉样肽的氨基末端精确切割淀粉样前体蛋白的能力。我们已分离并纯化出一种源自脑的活性物质,它能按照生成β-淀粉样肽氨基末端的要求,在甲硫氨酸和天冬氨酸残基之间切割合成肽底物SEVKMDAEF。其55 - 60 kDa的分子大小和抑制特性表明我们已纯化出金属蛋白酶EC 3.4.24.15。我们比较了EC 3.4.24.15、组织蛋白酶D和组织蛋白酶G切割模型肽SEVKMDAEF或含有据报道可调节β-淀粉样肽生成的取代基的相关肽的序列特异性。我们还测试了这些酶从全长的、膜嵌入的淀粉样前体蛋白底物或含有瑞典KM→NL突变的淀粉样前体蛋白形成羧基末端片段的能力。用针对β-淀粉样肽游离氨基末端的特异性抗体测试了正确切割情况。我们的结果排除了EC ⒊4.24.15作为候选β-分泌酶的可能性。尽管组织蛋白酶G能正确切割模型肽,但其切割瑞典KM→NL肽的能力较差,且不能生成与氨基末端特异性抗血清发生免疫反应的羧基末端片段。组织蛋白酶D不切割模型肽,对野生型淀粉样前体蛋白也无特异性;然而,它能恰当地切割瑞典“NL肽”和“NL前体”底物。我们的结果表明,在瑞典型家族性阿尔茨海默病中组织蛋白酶D可能充当β-分泌酶,并证明了使用全长底物验证候选蛋白酶序列特异性的重要性。